Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengdu Okay Pharmaceutical CoBJSE:920230 73 PB Ratio is 2.84 as of Sep. 10, 2026, which is 11% above its 10-year median of 2.56. GuruFocus rates BJSE:920230 with a GF Score™ of 73/100 and a GF Value™ of ¥11.12 (Fairly Valued). The stock has 7 warning signs investors should review. Among 918 Drug Manufacturers companies, Chengdu Okay Pharmaceutical Co ranks worse than 64.16% on this metric.
The historical rank and industry rank for Chengdu Okay Pharmaceutical Co's PB Ratio or its related term are showing as below:
BJSE:920230'
s PB Ratio Range Over the Past 10 Years
Min: 1.62 Med: 2.56 Max: 5.3
Current: 2.84
During the past 13 years, Chengdu Okay Pharmaceutical Co's highest PB Ratio was 5.30. The lowest was 1.62. And the median was 2.56.
BJSE:920230's PB Ratio is ranked worse than 64.16% of 918
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BJSE:920230: 2.84
During the past 12 months, Chengdu Okay Pharmaceutical Co's average Book Value Per Share Growth Rate was 1.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 23.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 19.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Chengdu Okay Pharmaceutical Co was 54.90% per year. The lowest was 1.50% per year. And the median was 18.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Chengdu Okay Pharmaceutical Co PB Ratio Related Terms
Chengdu Okay Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengdu Okay Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Okay Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengdu Okay Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Chengdu Okay Pharmaceutical Co's PB Ratio falls into.
Chengdu Okay Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chengdu Okay Pharmaceutical Co (BJSE:920230) has a PB Ratio of 2.84 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chengdu Okay Pharmaceutical Co and its competitors. This is 11% above median its historical median of 2.56. Over the past decade, Chengdu Okay Pharmaceutical Co's PB Ratio has ranged from 1.62 to 5.30. According to the industry distribution chart, Chengdu Okay Pharmaceutical Co ranks #589 out of 918 companies in the Drug Manufacturers industry, placing it in the top 64.2%.
Is Chengdu Okay Pharmaceutical Co's PB Ratio too high?
Chengdu Okay Pharmaceutical Co's current PB Ratio of 2.84 is 11% above median its 10-year median of 2.56. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 5.30. The Drug Manufacturers industry median PB Ratio is 1.98. Chengdu Okay Pharmaceutical Co's value of 2.84 is 43.4% above this industry median. Based on the distribution chart, Chengdu Okay Pharmaceutical Co ranks #589 out of 918 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chengdu Okay Pharmaceutical Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Okay Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chengdu Okay Pharmaceutical Co ranks #589 out of 918 companies for PB Ratio. This places Chengdu Okay Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.98. Chengdu Okay Pharmaceutical Co's value of 2.84 is 43.4% above this benchmark. Historically, Chengdu Okay Pharmaceutical Co's own PB Ratio has ranged from 1.62 to 5.30 over the past decade. While the company's 10-year median is 2.56 vs. the industry median of 1.98, Chengdu Okay Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Okay Pharmaceutical Co's current PB Ratio of 2.84 is 43.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chengdu Okay Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Okay Pharmaceutical Co's current PB Ratio is 2.84, which is 11% above median its own 10-year median of 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Okay Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co (BJSE:920230) is currently considered Fairly Valued. The stock's GF Value™ is ¥11.12, compared to a current price of ¥11.64 — trading 4.7% above its estimated fair value. The current PB Ratio is 2.84, which is 11% above median its 10-year median of 2.56 and 43.4% above the Drug Manufacturers industry median of 1.98. Chengdu Okay Pharmaceutical Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chengdu Okay Pharmaceutical Co (BJSE:920230), the current PB Ratio is 2.84 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Okay Pharmaceutical Co (BJSE:920230) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.64 is trading 4.7% above its estimated GF Value™ of ¥11.12.
GuruFocus considers Chengdu Okay Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920230:
PB Ratio: 2.84 (11% above median its 10-year median of 2.56)
GF Value™: ¥11.12 vs. price of ¥11.64 (4.7% above fair value)
Industry Position: 43.4% above the Drug Manufacturers median (#589 of 918)
No single metric tells the full story. See the BJSE:920230 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Okay Pharmaceutical Co Ltd engages in research and development, production, and sales of plant extracts. It specializes in natural vitamin P products, including large-scale professional planting, extraction, purification, synthesis, and application. Its product series include Citrus Extract Series, Sophorae Japonica Series, and Miscellaneous Extract Series.
73GF Score
Get the complete analysis for BJSE:920230
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920230 has been successfully added to your 
